Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats

American Journal of Respiratory Cell and Molecular Biology

Volumn 51, Issue 3, 2014, Pages 413-425

  Farkas, Daniela ^a   Alhussaini, Aysar A ^a   Kraskauskas, Donatas ^a   Kraskauskiene, Vita ^a   Cool, Carlyne D ^b   Nicolls, Mark R ^c   Natarajan, Ramesh ^a   Farkas, Laszlo ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Inflammation; Lymphocytes; Proliferation; Pulmonary hypertension

Indexed keywords

APOPTOSIS; INFLAMMATION; LYMPHOCYTES; PROLIFERATION; PULMONARY HYPERTENSION;

ANIMALS; ANOXIA; ANTIGENS, CD45; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; HYPERTENSION, PULMONARY; INDOLES; INFLAMMATION; INTERLEUKIN-6; LUNG; NF-KAPPA B; PULMONARY ARTERY; PYRROLES; PYRROLIDINES; RATS; SIGNAL TRANSDUCTION; THIOCARBAMATES; TIME FACTORS;

EID: 84906874342     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0355OC     Document Type: Article

References (50)

1. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012;122:4306-4313.
2. Erzurum S, Rounds SI, Stevens T, Aldred M, Aliotta J, Archer SL, Asosingh K, Balaban R, Bauer N, Bhattacharya J, et al. Strategic plan for lung vascular research: an NHLBI-ORDR workshop report. Am J Respir Crit Care Med 2010;182:1554-1562.
3. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54(Suppl):S10-S19.
4. Price LC, Wort SJ, Perros F, Dorfmüller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M. Inflammation in pulmonary arterial hypertension. Chest 2012;141:210-221.
5. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:897-908.
6. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-285. (Pubitemid 24165948)
7. Rahman A, Fazal F. Blocking nf-kappab: an inflammatory issue. Proc Am Thorac Soc 2011;8:497-503.
8. Brasier AR. The nuclear factor-κb-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 2010;86:211-218.
9. Yu Y, Keller SH, Remillard CV, Safrina O, Nicholson A, Zhang SL, Jiang W, Vangala N, Landsberg JW, Wang J-Y, et al. A functional single-nucleotide polymorphism in the trpc6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation 2009;119:2313-2322.
10. Huang J, Kaminski PM, Edwards JG, Yeh A, Wolin MS, Frishman WH, Gewitz MH, Mathew R. Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol 2008;294:L1250-L1259.
11. Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, Yamamoto H, Imanaka-Yoshida K, Shimpo H, Mizoguchi A, et al. A nuclear factor-kappab inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 2007;132:1265-1274. (Pubitemid 47621003)
12. Kimura S, Egashira K, Chen L, Nakano K, Iwata E, Miyagawa M, Tsujimoto H, Hara K, Morishita R, Sueishi K, et al. Nanoparticle-mediated delivery of nuclear factor kappab decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 2009;53:877-883.
13. Hosokawa S, Haraguchi G, Sasaki A, Arai H, Muto S, Itai A, Doi S, Mizutani S, Isobe M. Pathophysiological roles of nf-kb in pulmonary arterial hypertension: effects of synthetic selective nf-kb inhibitor imd-0354. Cardiovasc Res 2013;99:35-43.
14. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the vegf receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-438. (Pubitemid 32141434)
15. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100:923-929. (Pubitemid 46555698)
16. Ikeda Y, Yonemitsu Y, Kataoka C, Kitamoto S, Yamaoka T, Nishida K, Takeshita A, Egashira K, Sueishi K. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2002;283:H2021-H2028. (Pubitemid 35217037)
17. Sanchez O, Marcos E, Perros F, Fadel E, Tu L, Humbert M, Dartevelle P, Simonneau G, Adnot S, Eddahibi S. Role of endothelium-derived cc chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007;176:1041-1047. (Pubitemid 350127849)
18. Mizuno S, Farkas L, Al Husseini A, Farkas D, Gomez-Arroyo J, Kraskauskas D, Nicolls MR, Cool CD, Bogaard HJ, Voelkel NF. Severe pulmonary arterial hypertension induced by su5416 and ovalbumin immunization. Am J Respir Cell Mol Biol 2012;47:679-687.
19. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 2009;10:6.
20. Selimovic N, Bergh C-H, Andersson B, Sakiniene E, Carlsten H, Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009;34:662-668.
21. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009;104:236-244.
22. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W. Tgf-beta 1 plays an important role in the mechanism of cd4+cd25+ regulatory t cell activity in both humans and mice. J Immunol 2004;172:834-842. (Pubitemid 38113739)
23. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR Jr, et al. Regulatory t cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008;28:546-558.
24. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, et al. Right heart adaptation to pulmonary arterial hypertension: Physiology and pathobiology. J Am Coll Cardiol 2013;62(25 Suppl):D22-D33.
25. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009;120:1951-1960.
26. Ryan JJ, Marsboom G, Fang YH, Toth PT, Morrow E, Luo N, Piao L, Hong Z, Ericson K, Zhang HJ, et al. Pgc1alpha-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;187:865-878.
27. Price LC, Caramori G, Perros F, Meng C, Gambaryan N, Dorfmuller P, Montani D, Casolari P, Zhu J, Dimopoulos K, et al. Nuclear factor κ-b is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. PLoS ONE 2013;8:e75415.
28. Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, Bogaard HJ. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 2012; 302:L363-L369.
29. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-1631.
30. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1991;88:7605-7609. (Pubitemid 21915202)
31. Mouraret N, Marcos E, Abid S, Gary-Bobo G, Saker M, Houssaini A, Dubois-Rande JL, Boyer L, Boczkowski J, Derumeaux G, et al. Activation of lung p53 by nutlin-3a prevents and reverses experimental pulmonary hypertension. Circulation 2013;127:1664-1676.
32. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Böhm M, Nickenig G. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin ii type 1 receptor. Circ Res 2004;94:534-541. (Pubitemid 38326289)
33. Angelini DJ, Su Q, Yamaji-Kegan K, Fan C, Skinner JT, Champion HC, Crow MT, Johns RA. Hypoxia-induced mitogenic factor (himf/fizz1/relmα) induces the vascular and hemodynamic changes of pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2009; 296:L582- L593.
34. Farkas D, Kraskauskas D, Drake JI, Alhussaini AA, Kraskauskiene V, Bogaard HJ, Cool CD, Voelkel NF, Farkas L. Cxcr4 inhibition ameliorates severe obliterative pulmonary hypertension and accumulation of c-kit+ cells in rats. PLoS ONE 2014;9:e89810.
35. Wright CJ, Agboke F, Muthu M, Michaelis KA, Mundy MA, La P, Yang G, Dennery PA. Nuclear factor-κb (nf-κb) inhibitory protein iκbβ determines apoptotic cell death following exposure to oxidative stress. J Biol Chem 2012;287:6230-6239.
36. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. Nf-κb controls cell growth and differentiation through transcriptional regulation of cyclin d1. Mol Cell Biol 1999;19:5785-5799. (Pubitemid 29339933)
37. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005;19:1178-1180. (Pubitemid 40946457)
38. Itoh T, Nagaya N, Ishibashi-Ueda H, Kyotani S, Oya H, Sakamaki F, Kimura H, Nakanishi N. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 2006;11:158-163. (Pubitemid 43356895)
39. Perros F, Dorfmüller P, Montani D, Hammad H, Waelput W, Girerd B, Raymond N, Mercier O, Mussot S, Cohen-Kaminsky S, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185:311-321.
40. Tamosiuniene R, Tian W, Dhillon G, Wang L, Sung YK, Gera L, Patterson AJ, Agrawal R, Rabinovitch M, Ambler K, et al. Regulatory t cells limit vascular endothelial injury and prevent pulmonary hypertension / novelty and significance. Circ Res 2011;109:867-879.
41. Hillebrands JL, Whalen B, Visser JT, Koning J, Bishop KD, Leif J, Rozing J, Mordes JP, Greiner DL, Rossini AA. A regulatory cd41+ t cell subset in the bb rat model of autoimmune diabetes expresses neither cd25 nor foxp3. J Immunol 2006;177:7820-7832. (Pubitemid 44846298)
42. Gerondakis S, Siebenlist U. Roles of the nf-κb pathway in lymphocyte development and function. Cold Spring Harb Perspect Biol 2010;2:a000182.
43. Long M, Park S-G, Strickland I, Hayden MS, Ghosh S. Nuclear factor-κb modulates regulatory t cell development by directly regulating expression of foxp3 transcription factor. Immunity 2009;31:921-931.
44. Schuster M, Glauben R, Plaza-Sirvent C, Schreiber L, Annemann M, Floess S, Kühl Anja A, Clayton Linda K, Sparwasser T, Schulze-Osthoff K, et al. Iκbns protein mediates regulatory t cell development via induction of the foxp3 transcription factor. Immunity 2012;37:998-1008.
45. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF. Absence of t cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 2007;75:1280-1289. (Pubitemid 46905754)
46. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS, Gratwohl A. Endothelial injury mediated by cytotoxic t lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002;359:2078-2083. (Pubitemid 34680972)
47. Parel Y, Chizzolini C. Cd4+ cd8+ double positive (dp) t cells in health and disease. Autoimmun Rev 2004;3:215-220. (Pubitemid 38521097)
48. Eljaafari A, Yuruker O, Ferrand C, Farre A, Addey C, Tartelin ML, Thomas X, Tiberghien P, Simpson E, Rigal D, et al . Isolation of human cd4/cd8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory t cells and of a novel hla-dr7-restricted hy-specific cd4 clone. J Immunol 2013;190:184 - 194.
49. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of nf-kappab in the heart: to be or not to nf-kappab. Circ Res 2011;108:1122-1132.
50. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD. Cardiomyocyte nf-kappab p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res 2011;89:129-138.